-
2024-512276-35-00
4
2021-08-09
Multiple Myeloma
-
2023-506853-39-00
6
2021-05-20
Adynamic bone disorder
-
2023-505483-11-00
6
2021-05-02
Brain abscess
-
2023-504931-42-00
4
2021-04-06
Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters tran
-
2024-515365-34-00
6
2020-11-01
diabetic acute Charcot foot (Charcot neuroarthropathy)
-
2023-510527-29-00
4
2020-09-01
Cancer
-
2024-518384-36-00
4
2020-08-31
Idiopathic membranous nephropathy and severe proteinuria
-
2024-512186-14-00
6
2020-08-24
Fluid overload/fluid accumulation
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-515626-92-00
4
2013-10-18
recurrent/progressive medulloblastoma, ependymoma and atypical teratoi
-
2023-508055-40-00
6
2025-02-18
Obesity
-
2024-510719-31-00
5
2025-01-24
Moderate to Severe Vasomotor Symptoms (VMS)
-
2024-514228-18-00
4
2025-01-16
Asthma in adults who remain uncontrolled despite medium to high dose I
-
2024-513015-27-00
5
2025-01-09
Moderately to Severely Active Ulcerative Colitis (UC)
-
2024-511202-23-00
4
2024-10-31
Epithelial ovarian cancer that progressed on prior PARP inhibitor ther
-
2023-508096-36-00
5
2024-10-30
atopic dermatitis
-
2024-512676-36-00
10
2024-10-09
Langerhans Cell Histiocytosis
-
2023-505423-31-00
5
2024-08-08
advanced or metastatic gastric adenocarcinoma, gastroesophageal juncti
-
2023-506876-28-00
5
2024-08-01
The medical condition we are investigating is type 1 AMI (STEMI and NS
-
2023-508235-31-00
5
2024-06-17
Atopic Dermatitis
-
2023-506457-38-00
5
2024-06-05
Chronic kidney disease (CKD) and hypertension.